Cocaine-Binding Ligands Inhibit Beta-Amyloid Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's Disease are limited in effectively addressing the progression of the disease and reducing beta-amyloid peptide aggregation, with existing therapies mainly targeting neurotransmitter systems and showing only modest effects.
Innovation Solution
The use of cocaine-binding-site ligands and RNA aptamers that bind to beta-amyloid peptides to prevent aggregation, inhibit nicotinic acetylcholine receptor inhibition, and reduce tau phosphorylation, offering a unique trifunctional approach to address the major pathological processes of Alzheimer's Disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current Alzheimer's Disease treatments targeting neurotransmitter systems are used, then some symptomatic relief is achieved, but they show only modest effects and do not clearly affect disease progression
Solution Approach 1:
The invention uses ligands that bind to multiple targets simultaneously - cocaine-binding-site ligands that interact with both nicotinic acetylcholine receptors and beta-amyloid peptides. This multi-functionality allows a single compound to address both neurotransmitter deficits and amyloid aggregation, potentially achieving both symptomatic relief and disease modification that current single-target therapies cannot achieve
2Reliability
If new therapeutic agents targeting beta-amyloid aggregation are developed, then disease progression may be delayed, but the complexity of identifying effective compounds increases
Solution Approach 1:
The invention uses cocaine and its derivatives as intermediary compounds - substances with known pharmacological properties and binding characteristics that serve as starting points for developing anti-amyloid agents. This intermediary approach provides a familiar molecular framework that facilitates drug development and reduces the complexity of identifying effective compounds from scratch
3Ease of operation
If existing Alzheimer's treatments are administered, then some neurotransmitter-related symptoms are addressed, but they fail to prevent beta-amyloid peptide aggregation and tau phosphorylation
Solution Approach 1:
The invention merges two previously separate therapeutic approaches - cholinergic enhancement (via nicotinic acetylcholine receptor ligands) and anti-amyloid therapy (via beta-amyloid binding compounds) - into a single unified treatment strategy. This combination approach addresses multiple pathological processes simultaneously, including neurotransmitter deficits, amyloid aggregation, and potentially tau phosphorylation, thereby preventing key pathological processes that existing single-target therapies cannot prevent
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate the potential to prevent beta-amyloid aggregation, nicotinic acetylcholine receptor inhibition, and tau phosphorylation, providing a novel therapeutic strategy for treating and preventing Alzheimer's Disease by effectively targeting key pathological processes.
Implementation Method 1
cocaine-binding-site ligands and cocaine-binding-site RNA aptamers that bind with high affinity to a site (e.g., a cocaine-binding site) on beta-amyloid peptides and prevent their aggregation
Data Source
AI summary
The present invention relates to methods of using cocaine-binding-site ligands and cocaine-binding-site RNA aptamers to treat or prevent Alzheimer's Disease and to reduce or prevent aggregation of beta-amyloid peptides in a subject.